Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$2.44
+7.0%		$2.36
$1.19
▼
$3.60
$176.24M0.36602,255 shs255,705 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.87
$1.48
$0.87
▼
$2.44
$35.77M0.4826,109 shs187,703 shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$2.41
+5.2%		$2.70
$1.70
▼
$3.72
$172.41M0.93765,185 shs531,233 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.73
+0.1%		$0.77
$0.53
▼
$2.35
$157.72M2.833.74 million shs1.58 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
+1.79%+5.07%-11.28%-10.94%+62.86%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-10.84%-23.01%-47.59%-41.61%-57.56%
Nkarta, Inc. stock logo
NKTX
Nkarta
+4.09%+6.51%-32.25%-28.21%+9.57%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-7.51%-3.23%-21.11%-27.42%+7.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$2.44
+7.0%		$2.36
$1.19
▼
$3.60
$176.24M0.36602,255 shs255,705 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.87
$1.48
$0.87
▼
$2.44
$35.77M0.4826,109 shs187,703 shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$2.41
+5.2%		$2.70
$1.70
▼
$3.72
$172.41M0.93765,185 shs531,233 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.73
+0.1%		$0.77
$0.53
▼
$2.35
$157.72M2.833.74 million shs1.58 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
+1.79%+5.07%-11.28%-10.94%+62.86%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-10.84%-23.01%-47.59%-41.61%-57.56%
Nkarta, Inc. stock logo
NKTX
Nkarta
+4.09%+6.51%-32.25%-28.21%+9.57%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-7.51%-3.23%-21.11%-27.42%+7.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.33
Hold$8.00227.87% Upside
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
2.83
Moderate Buy$10.75346.06% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.86
Moderate Buy$4.00450.36% Upside

Current Analyst Ratings Breakdown

Latest BYSI, ABOS, NKTX, and TNYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/2/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Nkarta, Inc. stock logo
NKTX
Nkarta
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/23/2026
Nkarta, Inc. stock logo
NKTX
Nkarta
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
5/18/2026
Nkarta, Inc. stock logo
NKTX
Nkarta
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$9.00
5/18/2026
Nkarta, Inc. stock logo
NKTX
Nkarta
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
5/13/2026
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$1.16 per shareN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M20.44$0.10 per share8.59($0.59) per share-1.47
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/A$4.40 per shareN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$0.57 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.14N/AN/AN/AN/AN/A-14.00%8/12/2026 (Estimated)
Nkarta, Inc. stock logo
NKTX
Nkarta
-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$90.60M-$0.53N/AN/AN/AN/A-76.77%-61.96%8/12/2026 (Estimated)

Latest BYSI, ABOS, NKTX, and TNYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54N/AN/AN/A$8.77 millionN/A
8/12/2026Q2 2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.0683-$0.20-$0.1317-$0.20$10.00 million$1.11 million
8/11/2026Q2 2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.39N/AN/AN/AN/AN/A
8/11/2026Q2 2026
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.3603N/AN/AN/AN/AN/A
5/13/2026Q4 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A
5/12/2026Q1 2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.4028-$0.33+$0.0728-$0.33N/AN/A
5/12/2026Q1 2026
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.39-$0.37+$0.02-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.19
4.55
4.55
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
1.09
1.09
Nkarta, Inc. stock logo
NKTX
Nkarta
N/A
12.96
12.96
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
5.75
5.75

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Nkarta, Inc. stock logo
NKTX
Nkarta
80.54%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
10.20%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Nkarta, Inc. stock logo
NKTX
Nkarta
9.80%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2072.23 million64.86 millionOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8041.12 million29.07 millionOptionable
Nkarta, Inc. stock logo
NKTX
Nkarta
14071.54 million64.53 millionOptionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110217.00 million211.51 millionOptionable

Recent News About These Companies

Q3 Earnings Forecast for TNYA Issued By HC Wainwright
August 7 at 6:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-earnings-forecast-for-tnya-issued-by-hc-wainwright-2026-08-07/
Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results
August 5 at 7:55 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tenaya-therapeutics-nasdaqtnya-issues-quarterly-earnings-results-2026-08-05/
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339698/0/en/tenaya-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Wednesday
August 5 at 1:56 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30941449
Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday
August 5 at 1:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tenaya-therapeutics-tnya-to-post-earnings-on-wednesday-2026-08-05/
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338813/0/en/tenaya-therapeutics-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference.html
Cours Tenaya Therapeutics, Inc.
July 29, 2026  |  zonebourse.comZ
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages
July 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tenaya-therapeutics-inc-nasdaqtnya-given-average-recommendation-of-moderate-buy-by-brokerages-2026-07-17/
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327426/0/en/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Tenaya Therapeutics (NASDAQ:TNYA) Trading Down 3.9% - What's Next?
July 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tenaya-therapeutics-nasdaqtnya-trading-down-39-whats-next-2026-07-14/
Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block
July 13, 2026  |  donanimhaber.comD
Tenaya Names Eric Hyllengren as CFO
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/tenaya-names-eric-hyllengren-as-cfo-b43682b4
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318937/0/en/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer.html
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
June 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4912506-tenaya-therapeutics-inc-tnya-presents-at-jefferies-global-healthcare-conference-2026-prepared
Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)
June 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2309367/analysts-are-bullish-on-top-healthcare-stocks-ligand-pharma-lgnd-tenaya-therapeutics-tnya/
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...
June 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/tenaya-therapeutics-announces-interim-data-110000266.html
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305902/0/en/tenaya-therapeutics-announces-interim-data-from-mypeak-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-.html
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026
June 2, 2026  |  quiverquant.comQ
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305618/0/en/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b-2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026.html
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303537/0/en/tenaya-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-2026.html
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Knight Therapeutics (OtherKHTRF) and TScan Therapeutics (TCRX)
May 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TCRX/pressreleases/1829444/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-knight-therapeutics-otherkhtrf-and-tscan-therapeutics-tcrx/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$2.44 +0.16 (+7.02%)
Closing price 04:00 PM Eastern
Extended Trading
$2.35 -0.09 (-3.69%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$0.87 0.00 (0.00%)
Closing price 03:59 PM Eastern
Extended Trading
$0.87 0.00 (-0.34%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Nkarta stock logo

Nkarta NASDAQ:NKTX

$2.41 +0.12 (+5.24%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.00 (+0.21%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$0.73 +0.00 (+0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 +0.01 (+1.68%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas